Skip to main content

Miller Steve's Form 4 filing

Catalyst Pharmaceuticals, Inc. (CPRX) · filed Dec 11, 2024

Accession no.
0001161697-24-000505
Filed
Dec 11, 2024
Trade date
Dec 9-10, 2024
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.10M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Miller SteveCIK 0001402535Officer (Chief Op. & Scientific Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 9, 2024Common stock, par value $0.001 per shareMOption exerciseAcquired+11,872–F1–686,996Direct
Dec 10, 2024Common stock, par value $0.001 per shareMOption exerciseAcquired+50,000$4.01+$200,500736,996Direct
Dec 10, 2024Common stock, par value $0.001 per shareSSaleDisposed−50,000$21.93F2,F3−$1,096,500686,996Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 9, 2024Common StockMOption exerciseDisposed−11,872$0.00$01,837,176Direct
Dec 10, 2024Common StockMOption exerciseDisposed−50,000$0.00$01,787,176Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.

Referenced by the price of 1 transaction in Table I.

F2

Shares were sold on the open market for personal reasons and not as a result of any disagreement with the Company.

Referenced by the price of 1 transaction in Table I.

F3

Represents a weighted average price for the shares sold. Shares were sold in a range between $21.73 and $22.09 per share.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)